Peptide profile
KPV
Tripeptide for intestinal inflammation reduction
Compare KPV with other peptides →Summary
A tiny piece of a body protein that calms swelling in your tummy.
- Typical dose
- 0.1-0.5mg Daily
- Route
- Subcutaneous
- Cycle length
- 30-60 days
- Evidence
- Animal data
Mechanism
How it works
KPV works like a targeted fire extinguisher for gut inflammation — it recognizes intestinal tissue and puts out the flames.
Tripeptide derived from α-MSH inhibiting NF-κB activation and reducing pro-inflammatory cytokines in gut.
Reported in research
Benefits
- Strongly calms swelling for sore, upset guts
- Helps keep your gut lining strong
- Helps your body's defense team behave in the gut
Context, not a prescription
Dosing
- Typical range
- 0.1-0.5mg Daily (Subcutaneous)
- Cycle length
- 30-60 days
Safety
Side effects & contraindications
Possible side effects
- Mild injection site irritation
- Temporary nausea
- Slight fatigue
- Headache
- Dizziness
- Skin flushing
Contraindications
- Pregnancy or breastfeeding
- Autoimmune disease flares
- Known hypersensitivity
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Less gut swelling, a stronger gut lining, and a comfier tummy.
How it works
KPV is like a fire extinguisher for your gut. It finds the swelling and puts out the flames.
It connects to special spots on your gut's defense cells.
What to expect
Swelling goes down in about 1 to 3 weeks.
- Weeks 1-2: Less swelling in your gut.
- Weeks 3-4: Your tummy feels more comfy.
- Weeks 6-8: Your gut lining gets stronger.
Good to know
- Begin with a small dose (0.1mg)
- Watch how your tummy feels
- Use with BPC-157 so they work better together
Staying safe
- A little soreness where you got the shot
- Feeling sick to your stomach for a short time
- Feeling a bit tired
Avoid if you have:
- Women who are pregnant or breastfeeding
- People with flare-ups of immune diseases
- People who are allergic to it
Mechanism of action
Tripeptide derived from α-MSH inhibiting NF-κB activation and reducing pro-inflammatory cytokines in gut.
Binds to melanocortin receptors on immune cells in the intestinal mucosa.
Pharmacodynamics
Inflammation reduction within 1-3 weeks.
Reduced gut inflammation, improved barrier function, less digestive discomfort.
Timeline
- Weeks 1-2: Reduced gut inflammation.
- Weeks 3-4: Improved digestive comfort.
- Weeks 6-8: Enhanced intestinal barrier function.
Comparisons
- KPV — effectiveness Emerging, safety Good, cost $$, Easy to use
- BPC-157 — effectiveness Moderate, safety Good, cost $$, Medium to use
Adverse effects
Common:
- Mild injection site irritation
- Temporary nausea
- Slight fatigue
Rare:
- Headache
- Dizziness
- Skin flushing
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- Autoimmune disease flares
- Known hypersensitivity
- Start with lower dose (0.1mg)
- Monitor gut symptoms
- Use with BPC-157 for synergy
Qué hace
Menos hinchazón intestinal, un revestimiento intestinal más fuerte y un estómago más cómodo.
Cómo funciona
KPV es como un extintor de incendios para tu intestino. Encuentra la hinchazón y apaga las llamas.
Se conecta a puntos especiales en las células de defensa de tu intestino.
Qué esperar
La hinchazón disminuye en aproximadamente 1 a 3 semanas.
- Semanas 1-2: Menos hinchazón en tu intestino.
- Semanas 3-4: Tu estómago se siente más cómodo.
- Semanas 6-8: El revestimiento de tu intestino se fortalece.
Bueno saber
- Comenzar con una dosis pequeña (0,1 mg)
- Observar cómo se siente tu estómago
- Usar con BPC-157 para que funcionen mejor juntos
Manteniéndose seguro
- Un poco de dolor en el lugar de la inyección
- Sentirse con náuseas por un corto tiempo
- Sentirse un poco cansado
Evitar si tienes:
- Mujeres embarazadas o en lactancia
- Personas con brotes de enfermedades autoinmunes
- Personas alérgicas a este compuesto
Mecanismo de acción
Tri péptido derivado de α-MSH que inhibe la activación de NF-κB y reduce las citoquinas proinflamatorias en el intestino.
Se une a los receptores de melanocortina en las células inmunitarias de la mucosa intestinal.
Farmacodinamia
Reducción de la inflamación en 1-3 semanas.
Reducción de la inflamación intestinal, mejora de la función de barrera y menor malestar digestivo.
Cronología
- Semanas 1-2: Reducción de la inflamación intestinal.
- Semanas 3-4: Mejora del confort digestivo.
- Semanas 6-8: Función mejorada de la barrera intestinal.
Comparaciones
- KPV — efectividad Emergente, seguridad Buena, costo $$, Fácil de usar
- BPC-157 — efectividad Moderada, seguridad Buena, costo $$, Media de usar
Efectos adversos
Comunes:
- Irritación leve en el sitio de inyección
- Náuseas temporales
- Fatiga leve
Raros:
- Dolor de cabeza
- Mareos
- Enrojecimiento de la piel
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Brotes de enfermedades autoinmunes
- Hipersensibilidad conocida
- Comenzar con dosis baja (0,1 mg)
- Monitorear los síntomas intestinales
- Usar con BPC-157 para sinergia
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 30-60 days
FAQ
Common questions
Is KPV related to BPC-157?
Both are used for gut health — BPC-157 promotes tissue repair while KPV is primarily anti-inflammatory via α-MSH pathway.
What is the evidence level?
This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Research
Research & sources
Current evidence for KPV is rated as Animal data. Research is based primarily on animal models.
- 1. KPV in IBD models (2018) — DOI:10.3389/fimmu.2018.00517
- 2. KPV in IBD models (2018)